OR-OPEN19-FOUNDATION
4.6.2019 12:02:07 CEST | Business Wire | Press release
The Open19 Foundation, an organization established to create a community for a new generation of open data centers and edge solutions, today announced its membership within the Kinetic Edge™ Alliance (KEA) as a technology partner. The future of computing is at the edge, and this partnership will accelerate deployment of Open19 infrastructure into edge locations.
“The Kinetic Edge Alliance is the de-facto alliance that is creating order and a blueprint to build the edge technology specifically for edge cloud applications,” said Yuval Bachar, Open19 Foundation President. “The Open19 Foundation will join the Kinetic Edge Alliance to add the hardware buildout building block to the alliance with the Open19 platform. The Open19 platform is designed for the edge and optimized for the solution as defined by the Kinetic Edge alliance. It will enable a standard but flexible solution for building the Edge platforms of the present and the future.”
Founded by Open19 Foundation member company Vapor IO , the Kinetic Edge Alliance is an industry working group dedicated to making edge computing easy and connecting stakeholders with end users and customers. Other members of the group include Packet, New Continuum Data Centers, and Seagate. Learn more about the Alliance here .
“The Open19 standard makes it fast and economical to deploy equipment in edge environments,” said Matt Trifiro, CMO of Vapor IO. “By offering a chassis design that slides in and out of a rack, installing or swapping out data center equipment becomes almost as easy as opening and closing a desk drawer. This makes it possible for technicians to deploy or repair edge equipment in minutes instead of hours or days.”
Twelve partner companies launched the Kinetic Edge Alliance in February 2019 for the purpose of driving broad adoption of compute, storage, access and interconnection at the edge of the cellular network, simplifying edge computing for the masses. The Alliance is actively rolling out equipment and services across the top 30 major metropolitan US markets, beginning with the first six markets in 2019. The Alliance seeks to deploy, in lockstep, all of the key hardware and software infrastructure components that will enable commercial-grade edge computing at scale. There are now nearly 40 partner companies in the Alliance.
About the Open19 Foundation
The Open19 Foundation was established in 2017 by founding members Flex, GE Digital, Hewlett Packard Enterprise, LinkedIn, Packet, and Vapor IO to create a community that will enable a common optimized data center and edge solutions. It has since grown to 26 members from all parts of the edge ecosystem – from component and system suppliers and integrators, to data center operators. For more information, visit the Foundation’s website at www.open19.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005313/en/
Contact:
Open19 Foundation Rachael Watson, PR manager rwatson@nereus-worldwide.com (971) 706-1312
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom